<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1135-5727</journal-id>
<journal-title><![CDATA[Revista Española de Salud Pública]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Esp. Salud Publica]]></abbrev-journal-title>
<issn>1135-5727</issn>
<publisher>
<publisher-name><![CDATA[Ministerio de Sanidad]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1135-57272023000100105</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Utilidad de la app Abeona Health® para la participación del paciente en la identificación de toxicidad inducida por quimioterapia según la clasificación CTCAE]]></article-title>
<article-title xml:lang="en"><![CDATA[Utility of the Abeona Health® app for patient participation in the identification of chemotherapy-induced toxicity according to the CTCAE classification]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Miguel Barbero]]></surname>
<given-names><![CDATA[Carlota de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gea Rodríguez]]></surname>
<given-names><![CDATA[Elvira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garcia Cuyàs]]></surname>
<given-names><![CDATA[Francesc]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Andorra Escuela Internacional de Doctorado ]]></institution>
<addr-line><![CDATA[Andorra ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Andorra Grupo de investigación en Ciencias de la Salud y Servicios Sanitarios ]]></institution>
<addr-line><![CDATA[Andorra ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Andorra Escuela internacional de Doctorado Grupo de investigación en Ciencias de la Salud y Servicios Sanitarios]]></institution>
<addr-line><![CDATA[Mataró ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Andorra Grupo de investigación en Ciencias de la Salud y Servicios Sanitarios ]]></institution>
<addr-line><![CDATA[Andorra ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>97</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1135-57272023000100105&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1135-57272023000100105&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1135-57272023000100105&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamentos: Desde 2003, el Instituto Nacional del Cáncer (NCI) de los Estados Unidos de América ha sido uno de los líderes mundiales en la clasificación de los Efectos Adversos (EA). Actualmente, los teléfonos inteligentes permiten, entre otras muchas cosas, la monitorización de estos EA de la quimioterapia desde el domicilio para mejorar la seguridad y la calidad de vida de los pacientes. El objetivo de este estudio fue realizar un análisis comparativo descriptivo del contenido de los EA de la aplicación Abeona Health® y la última versión de los CTCAE (Common Terminology Criteria for Adverse Events).  Métodos: Se utilizó la app Abeona Health® y la guía CTCAE v5. Posteriormente, se analizaron los EA más recurrentes en el tratamiento quimioterápico, según la NCI y la Sociedad Española de Oncología Médica (SEOM) y, finalmente, si los pacientes podían identificarlos.  Resultados: El CTCAE v5 recoge 837 EA, donde 225 son signos y síntomas. El NCI clasifica cincuenta y cinco signos y síntomas como los más recurrentes, y la SEOM dieciséis, de los cuales quince coinciden con el NCI. La aplicación Abeona Health® dispone de siete EA, y todos se incluyen en el CTCAE v5. De estos siete, seis aparecen en las listas de EA más recurrentes del NCI y cuatro en la de la SEOM, todos ellos identificables por el paciente.  Conclusiones: La app de Abeona Health® se considera adecuada para la participación del paciente en su autocuidado, si bien se podrían ampliar algunos campos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background: Since 2003, the National Cancer Institute (NCI) of the United States of America has been one of the world leaders in classifying adverse effects (AEs). Currently, smartphones allow, among many other things, the monitoring of these AEs of chemotherapy from home to improve the safety and quality of life of patients. The aim was to perform a descriptive comparative analysis of the AEs content of the Abeona Health® app and the latest version of the CTCAE (Common Terminology Criteria for Adverse Events).  Methods: The Abeona Health® app and the CTCAE v5 guide were used. Subsequently, the most recurrent AEs in the existing chemotherapy treatment were analysed according to the NCI and the Spanish Society of Medical Oncology (SEOM) and finally, whether patients could identify them.  Results: The CTCAE v5 (collects 837 AEs), where two hundred and twenty-five are signs and symptoms. The NCI classifies fifty-five signs and symptoms as the most recurrent, and the SEOM sixteen, of which fifteen coincide with the NCI. The Abeona Health® application has seven AEs, all included in the CTCAE v5. Of these seven, six appear in the NCI lists of most recurrent AEs and four in the SEOM list, all identifiable by the patient.  Conclusions: The Abeona Health® app is considered adequate for the patient participation in their self-care, although some fields could be expanded.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermería]]></kwd>
<kwd lng="es"><![CDATA[Farmacia]]></kwd>
<kwd lng="es"><![CDATA[Cáncer]]></kwd>
<kwd lng="es"><![CDATA[Toxicidad]]></kwd>
<kwd lng="es"><![CDATA[Aplicaciones Móviles]]></kwd>
<kwd lng="es"><![CDATA[Empoderamiento para la salud]]></kwd>
<kwd lng="es"><![CDATA[Telemedicina]]></kwd>
<kwd lng="es"><![CDATA[Oncología Médica]]></kwd>
<kwd lng="en"><![CDATA[Nursing]]></kwd>
<kwd lng="en"><![CDATA[Chemistry]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
<kwd lng="en"><![CDATA[Toxicity]]></kwd>
<kwd lng="en"><![CDATA[Mobile Applications]]></kwd>
<kwd lng="en"><![CDATA[Empowerment for health]]></kwd>
<kwd lng="en"><![CDATA[Telemedicine]]></kwd>
<kwd lng="en"><![CDATA[Clinical Oncology]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia-Cuyàs]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[de San Pedro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Roldan Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La salud digital como motor de cambio hacia nuevos modelos asistenciales y de relación entre los pacientes y los profesionales de la salud. La disrupción de los procesos asistenciales]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2015</year>
<volume>145</volume>
<numero>Supl 1</numero>
<issue>Supl 1</issue>
<page-range>38-42</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>World Health Organization</collab>
<article-title xml:lang=""><![CDATA[Global Difussion of eHealth: Making universal health coverage achievable. Report of the third global survey on eHealth]]></article-title>
<source><![CDATA[mHealth]]></source>
<year>2016</year>
<page-range>27-73</page-range><publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>European Comission</collab>
<source><![CDATA[Green paper on mobile Health (mHealth)]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<source><![CDATA[The Growing Value of Digital Health: Evidence and Impact on Human Health and the Healthcare System]]></source>
<year>2017</year>
<publisher-loc><![CDATA[U.S. ]]></publisher-loc>
<publisher-name><![CDATA[IQVIA Institute for Human Data Science]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>Abeona Health</collab>
<source><![CDATA[Abeona app]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>American Society of Clinical Oncology</collab>
<source><![CDATA[Cancer.net]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Pfizer</collab>
<source><![CDATA[This is living with cáncer]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oruño]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Becerra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Piera]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Mateos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Emparanza]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<source><![CDATA[Sistemas de e-Salud para el Apoyo a Pacientes Oncológicos: Propuesta de Diseño para futuros Estudios Evaluativos. Igualada]]></source>
<year>2015</year>
<publisher-name><![CDATA[Agencia de evaluación de Tecnologías Sanitarias del País Vasco]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>Trilema Salud</collab>
<source><![CDATA[EMMA E-Oncosalud]]></source>
<year>2022</year>
<publisher-name><![CDATA[EMMA E-Oncosalud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Fundación Trilema</collab>
<source><![CDATA[Proyectos de Salud. ONCOMMUN]]></source>
<year>2022</year>
<publisher-name><![CDATA[ICOnnecta]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Treatment Technologies &amp;Insights</collab>
<source><![CDATA[&amp;Insights, LLC]]></source>
<year>2022</year>
<publisher-name><![CDATA[ChemoWave]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>Medocity, INC.</collab>
<source><![CDATA[Cancer Global Cancer Support Network]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<source><![CDATA[Variant Medical Systems Finland Oy]]></source>
<year>2022</year>
<publisher-name><![CDATA[Noona]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>Malecare, INC</collab>
<source><![CDATA[Cancergraph]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Collado Borrell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Diseño e implementación de una aplicación móvil para el seguimiento farmacoterapéutico de pacientes en tratamiento con antineoplásicos orales]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Universidad compultense de Madrid: facultad de farmacia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garciamartín Cerezo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Juvé Udina]]></surname>
<given-names><![CDATA[Mª Eulália]]></given-names>
</name>
<name>
<surname><![CDATA[Delago Hito]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Del concepto de empoderamiento del paciente a los instrumentos de medida: una revisión integrativa]]></article-title>
<source><![CDATA[Esc Enferm USP]]></source>
<year>2016</year>
<volume>50</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>664-71</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lettieri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empowering patients through eHealth: a case report of a pan-European project]]></article-title>
<source><![CDATA[BMC Health services research]]></source>
<year>2015</year>
<volume>15</volume>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Miguel Barbero]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Avellanet Viladomat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García Cuya&#768;s]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis descriptivo de las aplicaciones móviles del registro y seguimiento de los efectos adversos de los antineoplásicos según la metodología de evaluación del iSYScore y de la Fundación Tic Salut Social]]></article-title>
<source><![CDATA[Rev Esp Salud Pu&#769;blica]]></source>
<year>2022</year>
<volume>96</volume>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>U.S Department of health and human services. National Cancer Institute</collab>
<source><![CDATA[DCTD (Division of Cancer Treatment &amp; Diagnosis). Common Terminology Criteria for Adverse Events (CTCAE)]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Side effects of cancer treatment]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<source><![CDATA[Toxicidades de los tratamientos oncológicos. Toxicidades más comunes]]></source>
<year>2019</year>
<publisher-name><![CDATA[SEOM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>Abeona Health</collab>
<source><![CDATA[Abeona App Apple store]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<collab>Abeona Health</collab>
<source><![CDATA[Abeona App Google Play]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<source><![CDATA[Common Terminology Criteria for Adverse Events (CTCAE) v5. U.S. U.S Department of health and human services]]></source>
<year>2017</year>
<publisher-name><![CDATA[National Cancer Institute. DCTD (Division of Cancer Treatment &amp; Diagnosis)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Delirium]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Fertility issues in boys and men with cáncer]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Fertility issues in girls and woman with cancer]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Side effects of cáncer treatment. Flu-Like symptoms caused by cáncer treatments]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Mouth and throat problems]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Nerve problems (peripheral neuropathy)]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Sexual health issues in men with cancer]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Sexual health issues in women with cancer]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Skin and nail changes during cáncer treatment]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Sleep problems in people with cancer]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[Cancer treatment. Side effects of cáncer treatment. Urinary and bladder problems]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nugali]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jagoe]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Abalo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Averse Effects of Cancer Chemotherapy: Anything New to improve Tolerance and Reduce Sequelae?]]></article-title>
<source><![CDATA[Frontiers in Pharmacology]]></source>
<year>2018</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forster]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Menard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dupuis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chernish]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse events among medical patients fter discharge from hospital]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2004</year>
<volume>170</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>345-9</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ross Baker]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Norton]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Flintoft]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Blais]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Canadian Adverse Events Study: the incidende of adverse events among hospital patients in Canada]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2004</year>
<volume>170</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1678-86</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[La farmacovigilancia: garantía de seguridad en el uso de medicamentos. Perspectivas políticas sobre el uso de medicamentos de la OMS]]></source>
<year>2004</year>
<page-range>6-8</page-range><publisher-name><![CDATA[OMS/ED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Seguridad del paciente]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Información para las notificaciones de sospechas de reacciones adversas a medicamentos por parte de profesionales sanitarios]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Información para las notificaciones de sospechas de reacciones adversas a medicamentos por parte de ciudadanos]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[NCI Dictionary of Cancer Terms. Symptom]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="">
<collab>National Cancer Institute</collab>
<source><![CDATA[NCI Dictionary of Cancer Terms. Sign]]></source>
<year>2022</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
